Harvard Catalyst Profiles

P. ROSE 1, R. Edwards 2, N. Finkler 3, C. Duska 4, F. Cappuccini 5, T. Kolevska 6, E. Brand 7, K. Easley 8, J. Polikoff 9, U. Matulonis 4, C. Runowicz 1 1 Cleveland Clinic Foundation, Cleveland, OH, USA; 2 Magee Womens Hospital Of UPMC, Pittsburg, PA, USA; 3 Wright State University Florida State Cancer Institute, Orlando, FL, USA; 4 Harvard Affiliates Hospital, MA, USA; 5 Oregon Health & Science University, Portland, OR, USA; 6 Kaiser Permanente Hospital, Vallejo, CA, USA; 7 Sheridan Clinical Research, Pembroke, FL, USA; 8 Gynecology And Oncology Consultants, PC, St. Louis, MO, USA; 9 Kaiser Permanente, Southern California Medical Group, San Diego, CA, USA; 10 University Of Connecticut Health Center/John Dempsey Hospital, Farmington, CT, USA . PHASE 3 STUDY: CANFOSFAMIDE (C, TLK286) PLUS CARBOPLATIN (P) VS LIPOSOMAL DOXORUBICIN (D) AS 2ND LINE THERAPY OF PLATINUM (PL) RESISTANT OVARIAN CANCER (OC) . International Journal of Gynecologic Oncology. 2007.